Citi Downgrades Regeneron, Citing 'Underappreciated' Risk
“We find it hard to believe that in current day and age RTH258 would not have a price impact, at minimum,” Karnauskas said in a Friday note, projecting a 25-percent price impact and 10-percent share impact. (See Karnauskas' track record here.)
With RTH258 in the picture, Citigroup forecasts Regeneron striking just $380 per share. Unrivaled, it could break $490, the analyst said.
The competitive setback to Eylea could be partially offset by Dupi sales, which Karnauskas anticipates generating $1.03 billion in 2018 against consensus estimates of $924 million. Physician surveys indicate an impending increase in prescriptions for both adults and adolescents.
“Given the bullish Dupi survey and unchallenged Eylea for next two years, investors may not worry just yet,” Karnauskas said. “However, we see RTH258 threat as real and do not see transformative catalysts near term. We like REGN long term as this is the only large cap company with self-sustainable innovation.”
At the time of publication, Regeneron was trading up slightly at $364.60.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.